What’s new in the 2021 app update:
• New content from the 2021 Update to the 2017 ECDP for Optimization of Heart Failure Treatment, including information regarding use of angiotensin receptor-neprilysin inhibitors (ARNIs) as de novo therapy, and sodium-glucose cotransporter-2 (SGLT2) inhibitors for heart failure.
• Updated app structure for improved user experience
• Updated and expanded Therapy Reference section
TreatHF helps clinicians confirm which therapies are suggested for their symptomatic heart failure patients with reduced ejection fraction (stage C HFrEF), and provides guidance on the use of each therapy.
• Enter patient indications
• Review individualized next steps for medical therapy
• Email or print a summary of the next steps
• Reference detailed information for
- Initiation, titration, and monitoring of each medication
- Guidance for optimizing your overall medication strategy
